NSCLC with squamous or nonsquamous histology research hub

A Phase 3, multicenter, randomized, open-label trial to compare the efficacy and safety of pembrolizumab (MK-3475) in combination with lenvatinib (E7080/MK-7902) versus docetaxel in previously treated participants with metastatic non-small cell lung cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and immunotherapy (LEAP-008)

This study looks at new treatments for advanced lung cancer that has already been treated. It compares a combination of two drugs (pembrolizumab and lenvatinib) to another drug (docetaxel) to see which is more effective and safer.